COL17A1 and autoimmune bullous skin disease: These cases emphasize the importance of a thorough history of pemphigoid and BP180 autoantibody status in psoriasis patients before initiating IL-17A inhibitor therapy, urging caution among clinicians when considering these biologics for patients with a pemphigoid history [61].